Eicosatetraenoic acid, 11-hydroxy- | 73179-92-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Eicosatetraenoic acid, 11-hydroxy-
• 英文别名: (2E,4E,6E,8E)-11-hydroxyicosa-2,4,6,8-tetraenoic acid
• CAS: 73179-92-7
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: CLXDHZYUOWXCIU-LYWLHXJBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof
  申请人：Lipomics Technologies, Inc.

  公开号：EP2607902A1

  公开（公告）日：2013-06-26

  Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.

  本文描述了评估受试者肝脏中甘油三酯水平的新方法，包括确定受试者体液样本中脂质代谢物的含量。这些方法可用于诊断和监测脂肪变性、非酒精性脂肪肝和非酒精性脂肪性肝病等肝脏疾病。
• Platform and system for digital personalized medicine
  申请人：Cognoa, Inc.

  公开号：US10839950B2

  公开（公告）日：2020-11-17

  The digital personalized medicine system uses digital data to assess or diagnose symptoms of a subject to provide personalized or more appropriate therapeutic interventions and improved diagnoses. The use of prioritized questions and answers with associated feature importance can be used to assess mental function and allow a subject to be diagnosed with fewer questions, such that diagnosis can be repeated more often and allow the dosage to be adjusted more frequently. Pharmacokinetics of the subject can be estimated based on demographic data and biomarkers or measured, in order to determine a treatment plan for the subject. Also, biomarkers can be used to determine when the patient may be at risk for experiencing undesirable side effects and the treatment plan adjusted accordingly.

  数字个性化医疗系统使用数字数据评估或诊断受试者的症状，以提供个性化或更合适的治疗干预和改进的诊断。使用具有相关特征重要性的优先级问题和答案，可用于评估心理功能，使受试者只需较少的问题就能得到诊断，从而可以更频繁地重复诊断，更频繁地调整剂量。受试者的药代动力学可以根据人口统计学数据和生物标志物进行估计或测量，以便确定受试者的治疗方案。此外，生物标志物还可用于确定患者何时有可能出现不良副作用，并相应调整治疗方案。
• MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND METHODS OF USE THEREOF
  申请人：Metabolon, Inc.

  公开号：EP2057473B1

  公开（公告）日：2014-11-12
• MEANS AND METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS
  申请人：Metanomics Health GmbH

  公开号：EP2507633A1

  公开（公告）日：2012-10-10
• MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER IN A SUBJECT
  申请人：metanomics Health GmbH

  公开号：EP2577314B1

  公开（公告）日：2018-01-31